Compare AbbVie Inc (ABBV) vs iShares Gold Trust (IAU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares Gold Trust — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while iShares Gold Trust trades at $76.7. The key difference: AbbVie Inc pays a 2.72% dividend while iShares Gold Trust pays none, and AbbVie Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| ABBV | IAU | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $261.07 | $101.57 |
52-Week Low | $184.85 | $61.62 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
IAU trades at $78.30, up 1.02% with a bearish technical signal from moving averages while oscillators show neutrality. The stock faces resistance near $79 with support at $78. Recent news highlights strong central bank gold buying and analyst optimism for gold prices, though immediate technical indicators suggest caution.
The outlook remains mixed with bullish long-term gold fundamentals supporting IAU, but near-term technical resistance and potential Fed policy shifts pose risks. Investors should weigh strong institutional gold demand against current overbought short-term signals and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
